BACKGROUND AND PURPOSE: This study investigated whether the alpha(1)-adrenoceptor responsiveness of the renal vasculature was altered in the state of hypertension combined with renal failure. EXPERIMENTAL APPROACH: Male spontaneously hypertensive rats (SHR) received cisplatin (5 mg kg(-1) i.p.) to induce renal failure. Seven days later, the rats were anaesthetized and the reductions in renal blood flow (RBF) to electrical renal nerve stimulation (RNS) and intrarenal administration of three adrenoceptor agonists (noradrenaline, phenylephrine and methoxamine) were determined before and after amlodipine, 5-methylurapidil, chloroethylclonidine or BMY 7378. KEY RESULTS: In renal failure SHR (RFSHR), RBF and creatinine clearance were significantly reduced (approximately 70%), while urine output and fractional sodium excretion were four and twenty-fold higher, respectively, compared to SHR. Vasoconstrictions induced by RNS or the adrenoceptor agonists were greater in RFSHR than SHR, and these responses were blunted by 5-methylurapidil, BMY 7378 and amlodipine in the SHR, while chloroethylclonidine had no effect. In the RFSHR, all renal vasoconstrictions were reduced by amlodipine and BMY 7378 but 5-methylurapidil attenuated those caused by RNS, noradrenaline and methoxamine while those to phenylephrine were enhanced. Chloroethylclonidine potentiated renal vasoconstrictor responses to methoxamine and phenylephrine but not RNS or noradrenaline in RFSHR. CONCLUSIONS AND IMPLICATIONS: These findings suggest alpha(1A)- and alpha(1D)-adrenoceptors mediated the renal vasoconstrictor responses in SHR and RFSHR. In the RFSHR, other alpha(1)-adrenoceptor subtypes, for example, alpha(1B)-adrenoceptors appeared to play a greater role.
BACKGROUND AND PURPOSE: This study investigated whether the alpha(1)-adrenoceptor responsiveness of the renal vasculature was altered in the state of hypertension combined with renal failure. EXPERIMENTAL APPROACH: Male spontaneously hypertensiverats (SHR) received cisplatin (5 mg kg(-1) i.p.) to induce renal failure. Seven days later, the rats were anaesthetized and the reductions in renal blood flow (RBF) to electrical renal nerve stimulation (RNS) and intrarenal administration of three adrenoceptor agonists (noradrenaline, phenylephrine and methoxamine) were determined before and after amlodipine, 5-methylurapidil, chloroethylclonidine or BMY 7378. KEY RESULTS: In renal failure SHR (RFSHR), RBF and creatinine clearance were significantly reduced (approximately 70%), while urine output and fractional sodium excretion were four and twenty-fold higher, respectively, compared to SHR. Vasoconstrictions induced by RNS or the adrenoceptor agonists were greater in RFSHR than SHR, and these responses were blunted by 5-methylurapidil, BMY 7378 and amlodipine in the SHR, while chloroethylclonidine had no effect. In the RFSHR, all renal vasoconstrictions were reduced by amlodipine and BMY 7378 but 5-methylurapidil attenuated those caused by RNS, noradrenaline and methoxamine while those to phenylephrine were enhanced. Chloroethylclonidine potentiated renal vasoconstrictor responses to methoxamine and phenylephrine but not RNS or noradrenaline in RFSHR. CONCLUSIONS AND IMPLICATIONS: These findings suggest alpha(1A)- and alpha(1D)-adrenoceptors mediated the renal vasoconstrictor responses in SHR and RFSHR. In the RFSHR, other alpha(1)-adrenoceptor subtypes, for example, alpha(1B)-adrenoceptors appeared to play a greater role.
Authors: C Bagnis; H Beaufils; C Jacquiaud; Y Adabra; C Jouanneau; G Le Nahour; M C Jaudon; R Bourbouze; C Jacobs; G Deray Journal: Nephrol Dial Transplant Date: 2001-05 Impact factor: 5.992
Authors: Dae Gill Kang; An Sook Lee; Yeun Ja Mun; Won Hong Woo; Youn Chul Kim; Eun Jin Sohn; Mi Kyong Moon; Ho Sub Lee Journal: Biol Pharm Bull Date: 2004-03 Impact factor: 2.233
Authors: Marina A Ryazanova; Larisa A Fedoseeva; Nikita I Ershov; Vadim M Efimov; Arcady L Markel; Olga E Redina Journal: BMC Genet Date: 2016-12-22 Impact factor: 2.797
Authors: Mohammed H Abdulla; Munavvar A Sattar; Edward J Johns; Nor A Abdullah; Md Abdul Hye Khan Journal: Eur J Nutr Date: 2011-03-04 Impact factor: 5.614
Authors: Mohammed H Abdulla; Munavvar A Sattar; Nor A Abdullah; Md Abdul Hye Khan; Kolla R L Anand Swarup; Edward J Johns Journal: Eur J Nutr Date: 2010-09-30 Impact factor: 5.614
Authors: Mohammed H Abdulla; Munavvar A Sattar; Nor A Abdullah; Abdul Hye Khan; Kolla R L Anand Swarup; Hassaan A Rathore; Raisa N Kazi; Fathihah Basri; Edward J Johns Journal: Ups J Med Sci Date: 2010-11-04 Impact factor: 2.384
Authors: Larisa A Fedoseeva; Marina A Ryazanova; Nikita I Ershov; Arcady L Markel; Olga E Redina Journal: BMC Genet Date: 2016-01-27 Impact factor: 2.797
Authors: Ashfaq Ahmad; Munavvar A Sattar; Maleeha Azam; Mohammed H Abdulla; Safia A Khan; Fayyaz Hashmi; Nor A Abdullah; Edward J Johns Journal: PLoS One Date: 2016-05-18 Impact factor: 3.240